Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Inclusion Criteria: * Diagnosis of primary AL amyloidosis of tissue * Relapsed and/or refractory AL amyloidosis * Has received daratumumab or Faspro in any prior line of therapy * Prior pomalidomide exposure allowed if ≥ PR achieved and no disease progression occurred within 60 days of last dose received * Measurable disease * Able to give voluntary written consent * Eastern Cooperative Oncology Group performance status and/or other performance status 0, 1, or 2. * Absolute neutrophil count (ANC) ≥ 1,000/mm3 and platelet count ≥ 75,000/mm3. * Total bilirubin ≤ 1.5 × the upper limit of the normal range (ULN) (Total bilirubin ≥ 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%) * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN. * eGFR ≥ 20 mL/min/1.73 m2 (as calculated by Modified Diet in Renal Disease (MDRD) formula) Exclusion Criteria: * Non-AL amyloidosis * Clinically overt myeloma * Prior exposure to non-daratumumab anti-CD38 monoclonal antibodies. * Clinically significant cardiac disease * Severe obstructive airway disease * Female patients who are lactating or have a positive serum pregnancy test during the screening period * Planned high-dose chemotherapy and autologous stem cell transplantation within 6, 28-day treatment cycles after starting on treatment. * Failure to have fully recovered (ie, ≤ Grade 1 toxicity) from the reversible effects of prior chemotherapy. * Major surgery within 14 days before enroll…